Clinical Trial Update: A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating darolutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Nubeqa (darolutamide)

Snippet

Sponsor: Bayer | Conditions: Metastatic Hormone-sensitive Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING